Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) rose 3.7% during trading on Thursday . The company traded as high as $153.89 and last traded at $153.89, with a volume of 274,630 shares changing hands. The stock had previously closed at $148.34.

ICPT has been the topic of a number of recent analyst reports. Leerink Swann reissued a “market perform” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, March 23rd. Cowen and Company reissued a “buy” rating and issued a $212.00 price objective on shares of Intercept Pharmaceuticals in a research report on Monday, March 28th. Credit Suisse Group AG initiated coverage on shares of Intercept Pharmaceuticals in a report on Wednesday, March 30th. They issued an “outperform” rating and a $200.00 target price for the company. Goldman Sachs Group Inc. initiated coverage on shares of Intercept Pharmaceuticals in a report on Wednesday, March 30th. They issued a “neutral” rating and a $114.00 target price for the company. Finally, JMP Securities restated a “buy” rating and issued a $200.00 target price on shares of Intercept Pharmaceuticals in a report on Wednesday, March 30th. Three analysts have rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $203.08.

The firm’s market capitalization is $3.77 billion. The firm’s 50-day moving average is $149.04 and its 200-day moving average is $133.83.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($5.17) EPS for the quarter, missing analysts’ consensus estimates of ($3.60) by $1.57. During the same period in the previous year, the business earned ($1.78) EPS. Analysts anticipate that Intercept Pharmaceuticals Inc. will post ($16.82) earnings per share for the current fiscal year.

In other news, CEO Mark Pruzanski sold 714 shares of the business’s stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $145.11, for a total transaction of $103,608.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Lisa Bright sold 251 shares of the business’s stock in a transaction on Wednesday, May 25th. The shares were sold at an average price of $137.50, for a total transaction of $34,512.50. Following the transaction, the insider now directly owns 18,855 shares of the company’s stock, valued at approximately $2,592,562.50. The disclosure for this sale can be found here.

Several institutional investors have recently made changes to their positions in ICPT. Rhumbline Advisers increased its position in shares of Intercept Pharmaceuticals by 0.7% in the fourth quarter. Rhumbline Advisers now owns 15,849 shares of the biopharmaceutical company’s stock valued at $2,367,000 after buying an additional 109 shares during the period. California State Teachers Retirement System increased its position in shares of Intercept Pharmaceuticals by 1.4% in the fourth quarter. California State Teachers Retirement System now owns 29,529 shares of the biopharmaceutical company’s stock valued at $4,410,000 after buying an additional 400 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Intercept Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,610 shares of the biopharmaceutical company’s stock valued at $5,468,000 after buying an additional 578 shares during the period. New York State Common Retirement Fund increased its position in shares of Intercept Pharmaceuticals by 2.2% in the fourth quarter. New York State Common Retirement Fund now owns 37,400 shares of the biopharmaceutical company’s stock valued at $5,586,000 after buying an additional 800 shares during the period. Finally, ProShare Advisors LLC increased its position in shares of Intercept Pharmaceuticals by 5.9% in the fourth quarter. ProShare Advisors LLC now owns 20,213 shares of the biopharmaceutical company’s stock valued at $3,019,000 after buying an additional 1,130 shares during the period.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.